PMID- 28707988
OWN - NLM
STAT- MEDLINE
DCOM- 20170901
LR  - 20181113
IS  - 1748-880X (Electronic)
IS  - 0007-1285 (Print)
IS  - 0007-1285 (Linking)
VI  - 90
IP  - 1077
DP  - 2017 Aug
TI  - First clinical report of helical tomotherapy with simultaneous integrated boost 
      for synchronous bilateral breast cancer.
PG  - 20170152
LID - 10.1259/bjr.20170152 [doi]
LID - 20170152
AB  - OBJECTIVE: Radiotherapy (RT) for synchronous bilateral breast cancer (SBBC) is 
      technically very challenging. This study reports the clinical feasibility, 
      dosimetry and safety of helical tomotherapy (HT) with simultaneous integrated 
      boost (SIB) in patients treated with adjuvant radiotherapy for SBBC. METHODS: 21 
      women with SBBC treated with HT from January 2013 to June 2016 were 
      retrospectively evaluated. Radiation lung toxicity was assessed using pulmonary 
      function test (PFT) and high-resolution computerized tomography scan (HRCT) scan 
      at baseline and 1 yearpost-RT in 18 patients. Survival was calculated using 
      Kaplan-Meier curves. Significance of the difference between pre- and post-RT PFT 
      values was assessed using paired t-test. RESULTS: The dose prescription was 50Gy 
      to the breast, chest wall or regional nodes and 61Gy to the tumour bed as SIB, 
      delivered in 25 fractions. Dosimetric outcome was excellent both for target 
      volumes and normal tissues. Acute skin and oesophageal toxicities were minimal. 
      Symptomatic radiation-induced pnuemonitis was not observed. Subclinical 
      radiological Grade I-II changes were apparent in 14 patients. Only one patient 
      developed Grade III radiological change whereas no change was documented for 
      three patients. PFTs did not show any significant change in any of the measured 
      parameters. At a median follow-up of 25 months, 3-year disease-free survival, 
      overall survival and loco-regional control were 65.6%, 83.3% and 85.7% 
      respectively. CONCLUSION: Women with SBBC can be safely treated with HT and this 
      is not associated with adverse short- to intermediate term radiation toxicity. 
      Advances in knowledge: This is the first report that establishes the safety of HT 
      for adjuvant RT using SIB technique in SBBC.
FAU - Wadasadawala, Tabassum
AU  - Wadasadawala T
AUID- ORCID: 0000-0003-2167-420X
AD  - 1 Department of Radiation Oncology, Advanced Centre for Treatment, Research and 
      Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
FAU - Jain, Shanu
AU  - Jain S
AD  - 1 Department of Radiation Oncology, Advanced Centre for Treatment, Research and 
      Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
FAU - Paul, Siji
AU  - Paul S
AD  - 2 Department of Medical Physics, Advanced Centre for Treatment, Research and 
      Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
FAU - Phurailatpam, Reena
AU  - Phurailatpam R
AD  - 2 Department of Medical Physics, Advanced Centre for Treatment, Research and 
      Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
FAU - Joshi, Kishore
AU  - Joshi K
AD  - 2 Department of Medical Physics, Advanced Centre for Treatment, Research and 
      Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
FAU - Popat, Palak
AU  - Popat P
AD  - 3 Department of Radio-diagnosis, Tata Memorial Hospital, Mumbai, India.
FAU - Tandon, Sandip
AU  - Tandon S
AD  - 4 Department of Pulmonary Medicine, Tata Memorial Hospital, Mumbai, India.
FAU - Alahari, Aruna
AU  - Alahari A
AD  - 5 Department of General Medicine, Tata Memorial Hospital, Mumbai, India.
FAU - Sarin, Rajiv
AU  - Sarin R
AD  - 1 Department of Radiation Oncology, Advanced Centre for Treatment, Research and 
      Education in Cancer, Tata Memorial Centre, Navi Mumbai, India.
LA  - eng
PT  - Journal Article
DEP - 20170714
PL  - England
TA  - Br J Radiol
JT  - The British journal of radiology
JID - 0373125
SB  - IM
MH  - Adult
MH  - Aged
MH  - Breast Neoplasms/*radiotherapy
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Middle Aged
MH  - Radiotherapy Dosage
MH  - Radiotherapy, Adjuvant
MH  - Radiotherapy, Intensity-Modulated/*methods
MH  - Retrospective Studies
PMC - PMC5858804
EDAT- 2017/07/15 06:00
MHDA- 2017/09/02 06:00
PMCR- 2018/08/01
CRDT- 2017/07/15 06:00
PHST- 2017/07/15 06:00 [pubmed]
PHST- 2017/09/02 06:00 [medline]
PHST- 2017/07/15 06:00 [entrez]
PHST- 2018/08/01 00:00 [pmc-release]
AID - 10.1259/bjr.20170152 [doi]
PST - ppublish
SO  - Br J Radiol. 2017 Aug;90(1077):20170152. doi: 10.1259/bjr.20170152. Epub 2017 Jul 
      14.